Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Lopinavir und Ritonavir (ATC-Code: J05AR10) innerhalb des Zeitraumes vom 01.10.2026 bis zum 30.09.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient combination of Lopinavir and Ritonavir (ATC code: J05AR10), AOK Niedersachsen. The Health Insurance Fund offers discount agreements to all interested pharmaceutical companies, without a selection decision, for the period until the entry into force of exclusive agreements following a formal procurement procedure according to the regulations of Part 4 of the GWB. The contract conclusions take place within the framework of an "open-house model" and serve as a bridge between the start of generic competition (patent expiry) and the awarding of exclusive contracts. The offered contracts are non-exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. Uniform conditions apply to all participants in the open-house model. Contract contents, conditions, and access procedures are uniform – individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, the earliest contract start is 01.10.2026. All contracts end at the latest on 30.09.2028, regardless of the date of the respective contract conclusion. Joining or contract conclusion can occur within the…

TENDER BRIEF

TENDER DOCUMENTS